Table 1.
Baseline characteristics according to values below median (more negative) (n = 65) or above median (more positive) (n = 52), median GLS (median = −11 %)
| Variable | Below median GLS | Above median GLS | p-value |
|---|---|---|---|
| (n = 65) | (n = 52) | ||
| Age, years | 69 (63–76) | 71 (67–76) | 0.761 |
| Female gender, % | 33.8 | 21.2 | 0.130 |
| BMIa, kg/m2 | 26.0 (22.6-30.2) | 26.3 (24.5-30.3) | 0.214 |
| NYHAb class III-IV, % | 23.1 | 30.8 | 0.349 |
| Systolic BPc, mmHg | 132 (120–147) | 120 (110–140) | 0.178 |
| Diastolic BPc, mmHg | 77 (70–82) | 77 (69–84) | 0.889 |
| Heart rate, beats/min | 64 (56–76) | 70 (62–78) | 0.188 |
| HFd duration, months | 9 (6–12) | 12 (6–24) | 0.216 |
| Pervious MIe, % | 33.8 | 44.2 | 0.251 |
| Hypertension, % | 67.7 | 59.6 | 0.395 |
| Atrial fibrillation, % | 24.6 | 40.4 | 0.068 |
| ICDf, % | 9.5 | 13.5 | 0.507 |
| Diabetes, % | 20 | 25 | 0.518 |
| ApoplexiaCerebri/TCIg, % | 12.3 | 23.1 | 0.124 |
| ACE-Ih, % | 73.8 | 59.6 | 0.140 |
| ARBi, % | 21.5 | 32.7 | 0.174 |
| Beta-blocker, % | 87.7 | 86.5 | 0.853 |
| MRAj, % | 14.1 | 28.8 | 0.051 |
| Diuretics, % | 69.2 | 76.9 | 0.354 |
| Hemoglobine, mmol/l | 8.5 (7.0-9.0) | 8.8 (8.0-9.3) | 0.215 |
| Creatinine, umol/l | 80 (68–97) | 95 (73–119) | 0.254 |
| eGFRk, ml/min/1,73 m2 | 82 (66–98) | 70 (51–95) | 0.244 |
aBody mass index, bNew York Heart Association, cBlood pressure, dHeart failure, eMyocardial infarction, fImplantable cardiac defibrillator, gTransitory cerebral ischemia, hAngiotensin converting enzyme inhibitor, iAldosterone receptor blocker, jMineralocorticoid receptor antagonist, kEstimated glomerular filtration rate